

## IMRICOR COMPLETES SUCCESSFUL A\$60 MILLION CAPITAL RAISE

### Highlights:

- Imricor has received firm commitments to raise A\$60.0 million (US\$43.2 million)<sup>1</sup> via a strongly supported placement to new and existing institutional, sophisticated and professional investors
- The placement was completed at an offer price of A\$1.85, representing a 6.3% discount to the Company's last traded price on Wednesday 29 April 2026
- Proceeds from the placement will be used to accelerate Imricor's growth strategy, including launching NorthStar in the U.S., advancing regulatory approvals for the full Electrophysiology (EP) platform, completing key clinical programs, progressing Pulsed Field Ablation (PFA) development, and supporting expansion in the Middle East and other target markets
- Following the raise, the Company is well capitalised to execute on its commercial, clinical and regulatory objectives
- The Company expects to have cash reserves of approximately A\$102.9 million (US\$74.1 million)<sup>1</sup> after costs following completion of the Placement<sup>2</sup>

**4 May 2026** – Melbourne, Australia (**3 May 2026** – Minneapolis, MN United States) – **Imricor Medical Systems, Inc. (Company or Imricor) (ASX: IMR)** is pleased to announce that it has received firm commitments for a placement to new and existing institutional and sophisticated investors to raise A\$60.0 million (US\$43.2 million)<sup>1</sup>, through the issue of 32.4 million new CHES Depositary Interests (representing the same number of shares of Class A common stock) (**New CDIs**) at an issue price of A\$1.85 per CDI (**Placement**).

### Placement details

The New CDIs will be issued in one tranche pursuant to the Company's existing placement capacity under ASX Listing Rule 7.1 (32,432,433 CDIs), and will be issued on the same terms as, and will rank equally with, all existing CDIs.

The issue price of A\$1.85 per CDI under the Placement represents a:

---

<sup>1</sup> Converted at exchange rate of A\$0.72/US\$1.00

<sup>2</sup> Based on Company's unaudited cash and marketable securities balances as at 31 March 2026



- 6.3% discount to the Company’s last closing price on ASX of A\$1.975 on Wednesday, 29 April 2026 (being the last trading day before the Company went into trading halt); and
- 7.7% discount to the Company’s 10-day VWAP on ASX of A\$2.00 up to, and including, Wednesday 29 April 2026.

The funds raised from the Placement, together with existing cash reserves, will be used to support the Company’s next phase of growth, including to:

- Launch NorthStar to customers in the U.S., including paediatric hospitals
- Secure regulatory approvals for the entire Electrophysiology (EP) platform in the U.S.
- Fund the commercial rollout in 2027 and beyond, targeting hospitals with existing CMR facilities as well as new greenfield sites
- Complete VISABL-VT clinical trial in Europe and launch VT ablations in Europe
- Invest in dedicated resources for Middle East expansion
- Commence VT trial in the U.S. in 2027 to expand U.S. indications
- Progress development of Pulsed Field Ablation (PFA) targeting Atrial Fibrillation in MR
- Expand portfolio of approved products such as biopsy catheter and other interventional tools
- Accelerate NorthStar development to increase functionality and broaden use cases beyond cardiology

The Placement is expected to settle on or around Thursday, 7 May 2026 with New CDIs expected to be allotted and commence trading on the ASX Friday, 8 May 2026

Morgans Corporate Limited, Canaccord Genuity (Australia) Limited and Taylor Collison Limited acted as Joint Lead Managers to the Placement.

**Imricor’s Chair and CEO, Steve Wedan, commented:** “Imricor has entered 2026 with strong regulatory momentum, expanding clinical validation, and growing commercial interest across multiple markets. This capital raise gives us the financial strength to move decisively from momentum to scale.

“With NorthStar now cleared in the U.S., our pediatric label expansion submitted, and the broader EP platform continuing to advance through the FDA process, we believe the Company is exceptionally well positioned. This raise allows us to invest behind that opportunity, expand our installed base, and continue building the world’s leading interventional MR platform.”

The indicative timetable for the Placement is as follows:

Event	Dates (AEST)
Company resumes trading and announcement of completion of Institutional Placement	Monday, 4 May 2026
Settlement of New CDIs under the Institutional Placement	Thursday, 7 May 2026
Allotment and Quotation of New CDIs under the Institutional Placement	Friday, 8 May 2026

\* The Placement timetable is indicative only and subject to variation. The Company reserves the right to alter the timetable at its discretion and without notice, subject to ASX Listing Rules and the Corporations Act.

For personal use only



Further details of the Placement are outlined in the investor presentation released on the ASX platform today.

## ENDS

Authorised for release by Steve Wedan, Executive Chair, President, and CEO.

### Media and Investor Relations Contacts:

Simon Hinsley  
Executive Director, NWR  
simon@nwrcommunications.com.au  
+61 401 909 653

Nick Corkill  
VP Corporate Strategy, Imricor  
nick.corkill@imricor.com  
+61 450 475 633

### About Imricor

Imricor Medical Systems, Inc. (ASX:IMR) is striving to make interventional medical procedures better, safer, and more cost effective by making it possible for these procedures to be performed under real-time magnetic resonance (MR) imaging guidance, rather than under x-ray fluoroscopy guidance, thus taking advantage of MR's superior imaging capabilities.

### Imricor's Products

Imricor is a pioneer and world leader in developing MR-compatible products for cardiac catheter ablation procedures. The Company's products include capital equipment, such as the NorthStar® Mapping System and the Advantage-MR® EP Recorder/Stimulator. Single-use devices include a variety of ablation catheters, diagnostic catheters, steerable sheaths, and other tools used for cardiac ablations.

Imricor's products are approved in the European Union, the Kingdom of Saudi Arabia, and New Zealand. NorthStar is approved in the US.

### Foreign Ownership Restrictions

Imricor's CHES Depositary Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons excluding qualified institutional buyers (QIBs, as defined in Rule 144A under the Securities Act). However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

### Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, EU commercial market acceptance and EU sales of our product as well as our expectations with respect to our ability to develop and commercialise new products. Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Imricor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of



new information, future events or otherwise. Imricor may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

For personal use only